ArticleThe American journal of pathology1996
Induction of Heymann nephritis with a gp330/megalin fusion protein.
Article in The American journal of pathology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Animal models of membranous nephropathy: more choices and higher similarity.Frontiers in immunology · 2024Review
- Sanqi Oral Solution Mitigates Proteinuria in Rat Passive Heymann Nephritis and Blocks Podocyte ApoptosisFrontiers in pharmacology · 2021Article
- Advances of the experimental models of idiopathic membranous nephropathy (Review).Molecular medicine reports · 2020Review
- A podocyte view of membranous nephropathy: from Heymann nephritis to the childhood human disease.Pflugers Archiv : European journal of physiology · 2017Review
- Abundance of megalin and Dab2 is reduced in syncytiotrophoblast during placental malaria, which may contribute to low birth weight.Scientific reports · 2016Article
- Artemisinin analogue SM934 ameliorates the proteinuria and renal fibrosis in rat experimental membranous nephropathy.Acta pharmacologica Sinica · 2015Article
- Pathogenesis of membranous nephropathy: recent advances and future challenges.Nature reviews. Nephrology · 2012Review
- Experimental Models of Membranous Nephropathy.Drug discovery today. Disease models · 2010Article
- Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men.Seminars in immunopathology · 2007Review
- Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model.International journal of experimental pathology · 2004Article
- Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats.International journal of experimental pathology · 2004Article
- Production of Heymann nephritis by a chemically modified renal antigen.International journal of experimental pathology · 2004Article
- Transcobalamin II receptor interacts with megalin in the renal apical brush border membrane.The Journal of membrane biology · 2003Article
- Targeting of thyroglobulin to transcytosis following megalin-mediated endocytosis: evidence for a preferential pH-independent pathway.Journal of endocrinological investigation · 2003Article
- Inhibition of complement regulation is key to the pathogenesis of active Heymann nephritis.The Journal of experimental medicine · 1998Article
- Pathogenic antibodies inhibit the binding of apolipoproteins to megalin/gp330 in passive Heymann nephritis.The Journal of clinical investigation · 1997Article
- The solution structure of the N-terminal domain of alpha2-macroglobulin receptor-associated protein.Proceedings of the National Academy of Sciences of the United States of America · 1997Article
- Identification of the second cluster of ligand-binding repeats in megalin as a site for receptor-ligand interactions.Proceedings of the National Academy of Sciences of the United States of America · 1997Article
- Molecular analysis of the pathological autoimmune antigens of Heymann nephritis.The American journal of pathology · 1996Review
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
There is considerable evidence that glomerular deposits in Heymann nephritis, a rat model of membranous nephritis, result from shedding of immune complexes formed on podocytes and that the principal antigen is part of the extracellular domain of a cell surface glycoprotein receptor called gp330 or megalin. It has also been reported that the immunogen that induces Heymann nephritis is a complex formed between gp330 and the receptor-associated protein RAP. The recent elucidation of the primary structure of gp330 makes it possible to investigate the ability of defined portions of gp330, devoid of RAP, to induce Heymann nephritis. In the present study we show that a gp330-glutathione-S-transferase fusion protein, containing 137 amino acid residues (1114 to 1250) of the ectodomain, induces active Heymann nephritis and that heterologous antibodies against this fusion protein produce passive Heymann nephritis. By immunofluorescence, typical glomerular immunoglobulin deposits were found, but complement components were lacking and the rats did not develop proteinuria. In the active model, we obtained evidence indicating that the deposits contained portions of the ectodomain of gp330, including regions other than those of the fusion protein. Thus, the deposits were stained by polyclonal antibodies to gp330 and to the gp330 fusion protein, as well as by two monoclonal antibodies reactive with portions of the ectodomain of gp330, only one of which reacted with the fusion protein in vitro. Antibodies against the cytoplasmic domain of gp330 did not stain. Furthermore, we found that RAP was able to bind to gp330 in the glomerular deposits but not to the gp330 fusion protein in vitro. The results show that the region of gp330 spanning amino acid residues 1114 to 1250 contains peptides capable of inducing pathogenic antibodies of Heymann nephritis without a contributory role of RAP.
Indexed as
Identifiers
8623929PMC1861581What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.